Cancer Metabolism Therapy with Rafael Pharmaceuticals

To Save A Life Is To Save A Universe

Developing innovative cancer therapies that will transform the way we treat patients.

Cancer Metabolism

Cancer Metabolism

A breakthrough approach to treating some of the most intractable forms of cancer

Breakthrough Cancer Therapies

Breakthrough Therapies

Rafael's proprietary AMD platform has produced a robust pipeline of breakthrough cancer therapies


To develop highly selective, well-tolerated, and highly effective anti-cancer agents, by selectively targeting cancer metabolism by inhibiting pro-cancer cells while preserving and stimulating anti-cancer immune system cells. Our immediate goal is to improve the quality of life of patients with pancreatic cancer, which is the deadliest cancer worldwide and has limited treatment options.


We aspire to be a high growth, fully integrated cancer metabolism therapeutics leader focused on improving and extending the lives of patients.

CPI-613® (devimistat)

Rafael Pharmaceutical’s first-in-class clinical lead compound, devimistat, targets enzymes that are involved in cancer cell metabolism and are located in the mitochondria of cancer cells. Devimistat is being evaluated in multiple  clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with rare solid tumors or blood cancers.

The U.S. Food and Drug Administration (FDA) has designated devimistat as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), peripheral T-cell lymphoma, Burkitt’s lymphoma and soft tissue sarcoma and biliary tract cancer. The European Medicines Agency (EMA) has granted orphan drug designation to devimistat for pancreatic cancer,  acute myeloid leukemia ( and AML) and Burkitt’s lymphoma. 

Learn More

World Class Team

Innovation in oncology drug development requires a deep well of scientific, medical and business expertise, and we have assembled an unparalleled team of directors and advisors who are working with Rafael to revolutionize anticancer treatment.

Our Board of Directors and Scientific & Medical Advisory Boards are drawn from the highest echelons of oncology and hematology researchers and physicians, and include seasoned managers from the biotech and pharmaceutical sectors.